CatSci makes new appointments to its Board to further continue strategic growth
15th September 2020
Cardiff, UK – CatSci Ltd, a scientifically led, commercially minded and award-winning innovation partner, has announced the appointment of Gary Lumby, MBE FCIOBS, and Stephanie Knowles as Non-Executive Director (NED) and Financial Director, respectively.
These important additions to the Board of Directors will help CatSci maximise its sustainable business growth. With a long-term goal of creating 500 high-value jobs by 2030, these appointments will ensure that investment decisions are continually adding value for customers. Moreover, this will allow more projects to be fulfilled – helping CatSci meet the evolving healthcare needs of the world, through the development of economically and environmentally sustainable chemical processes.
Gary Lumby, MBE FCIOBS, has been appointed as a NED to CatSci’s Board to deliver essential strategic and corporate governance, providing hands on support to help CatSci achieve optimal business growth, and ensure customers receive superlative service delivery. With vast experience in corporate banking, including leadership of Yorkshire and Clydesdale Banks, Gary has been a portfolio NED for many years, focused on high growth SMEs in the UK.
Alongside Gary, Stephanie Knowles has been appointed as Financial Director and will be working closely with the Senior Management Team to support CatSci’s growth and expansion plans. Stephanie’s broad experience in SMEs and start-up companies will provide CatSci with key financial insight, while driving value into the business through efficiency and effectiveness.
The news of these appointments comes at an exciting time for CatSci, who also announced the appointment of Shaw & Co as its corporate financial adviser. CatSci will use their expertise to help develop funding strategies to drive growth, further maximising the real value held within CatSci.
Gary Lumby, Non-Executive Director, said “I am delighted to be joining the Board of CatSci at this pivotal time in its development, where there are a number of exciting expansion opportunities being considered. I am sure that my expertise with other growth companies will greatly assist me in supporting the Directors and help to accelerate our growth trajectory in an exciting but manageable way.”
Stephanie Knowles, Financial Director, added “I will be working closely with the Senior Management Team to support the growth and expansion plans of CatSci, whilst driving value through the business.”
Dr Ross Burn, CEO, said: “It is fantastic to see CatSci continue to grow. Adding new members to our Board allows us to expand our work and keep to our long-term vision of growth. Gary was my mentor on the prestigious GS10kSB programme and we are delighted that he agreed to join the Board to help us achieve sustainable growth. We are also thrilled that Stephanie has joined the Board to aid informed decision making in what is a critical time for the company. Their experience and pedigree are an invaluable asset to our organisation.”
CatSci Ltd provides tailored process research and development services to emerging, mid-sized and large pharma. We proudly serve customers across the globe with projects, meeting their needs from IND-enabling through product launch. Our services include route scouting and selection for early development, and process design, development and optimisation for later development. As a scientifically led and commercially minded innovation partner with a proven track record, we are dedicated to optimising our customers’ drug substance manufacturing processes to enable them to create small molecule best-in-class therapeutics in a safer, greener and more cost-effective way. Together, we can meet the evolving healthcare needs of the world.
Ensuring open consultation and communication in everything we do, we take the time to understand our customers’ project objectives and then efficiently and effectively resolve the challenges that they face. CatSci is committed to ensuring it is the right investment for the research and development of economically and environmentally sustainable pharmaceutical manufacturing.
Recognition includes wins at the prestigious CPhI Pharma Awards 2018 (Excellence in Pharma: Contract Services and Outsourcing) and at the highly esteemed Cardiff Business Awards 2019 (International Business of the Year). We have also recently been shortlisted for the International Expansion Entrepreneur of the Year at the Barclays Entrepreneur Awards 2020, and for the 2020 Wales STEM Awards in both the STEM International Business of the Year and STEM Scale-Up of the Year categories.
Shelley Farrar Stoakes, Notch Communications
+44 (0) 161 818 9214